AR055428A1 - Escision de precursores de insulinas mediante una variante de tripsina - Google Patents

Escision de precursores de insulinas mediante una variante de tripsina

Info

Publication number
AR055428A1
AR055428A1 ARP060103963A ARP060103963A AR055428A1 AR 055428 A1 AR055428 A1 AR 055428A1 AR P060103963 A ARP060103963 A AR P060103963A AR P060103963 A ARP060103963 A AR P060103963A AR 055428 A1 AR055428 A1 AR 055428A1
Authority
AR
Argentina
Prior art keywords
variant
tripsine
execution
insulin precursors
recombinant
Prior art date
Application number
ARP060103963A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Sanofi Aventis Deutschland filed Critical Hoffmann La Roche
Publication of AR055428A1 publication Critical patent/AR055428A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se refiere a la produccion de una variante de tripsina recombinante con especificidad incrementada el sustrato para arginina frente a lisina en organismos huéspedes no animales. Además, se refiere a una variante de tripsina recombinante y a su produccion. También se proporciona el uso de variantes de tripsina pancreática porcina recombinante para la escision de precursores de insulinas, y kits que contienen la variante de tripsina.
ARP060103963A 2005-09-14 2006-09-12 Escision de precursores de insulinas mediante una variante de tripsina AR055428A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05077086 2005-09-14

Publications (1)

Publication Number Publication Date
AR055428A1 true AR055428A1 (es) 2007-08-22

Family

ID=36190640

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103963A AR055428A1 (es) 2005-09-14 2006-09-12 Escision de precursores de insulinas mediante una variante de tripsina

Country Status (20)

Country Link
US (1) US7981635B2 (es)
EP (1) EP1926749B1 (es)
JP (1) JP5027812B2 (es)
KR (1) KR101304958B1 (es)
CN (1) CN101253196B (es)
AR (1) AR055428A1 (es)
AT (1) ATE517919T1 (es)
AU (1) AU2006291780B2 (es)
BR (1) BRPI0616054B8 (es)
CA (1) CA2621344C (es)
CY (1) CY1112667T1 (es)
ES (1) ES2370657T3 (es)
HK (1) HK1124341A1 (es)
IL (1) IL189887A (es)
MX (1) MX2008003362A (es)
MY (1) MY146082A (es)
PL (1) PL1926749T3 (es)
PT (1) PT1926749E (es)
SI (1) SI1926749T1 (es)
WO (1) WO2007031187A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN102015762B (zh) * 2008-02-19 2015-03-18 百康有限公司 获得纯化的生物活性异源蛋白的方法
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
WO2011030347A1 (en) * 2009-09-10 2011-03-17 Biocon Limited Novel prolipase-bovine trypsinogen fusion proteins
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013015697A1 (en) * 2011-07-28 2013-01-31 Mabion S.A. A recombinant protein, a polynucleotide encoding it as well as a method of obtaining insulin or its an analogue
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
DK2831262T3 (en) * 2012-03-29 2018-05-28 Biocon Ltd SECRETION OF FUNCTIONAL INSULIN GLARGIN DIRECTLY IN THE CULTIVATION MEDIUM THROUGH INTRACELLULAR OVERPRESSION OF KEX2P
CN102816785B (zh) * 2012-05-24 2016-03-09 上海仁会生物制药股份有限公司 一种甘精胰岛素及其类似物的制备方法
CN102994600A (zh) * 2012-12-11 2013-03-27 鲁南新时代生物技术有限公司 甘精胰岛素前体的酶切转化方法
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108018277A (zh) * 2016-11-04 2018-05-11 江苏万邦生化医药股份有限公司 重组牛胰蛋白酶突变体及其制备方法
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
CA3091943A1 (en) * 2018-02-22 2019-08-29 Sanofi-Aventis Deutschland Gmbh Variants of porcine trypsin
EP3650541A1 (en) * 2018-11-08 2020-05-13 BioPharma Translationsinstitut Dessau Forschungs GmbH Trypsin mutant for c- and n-terminal modification of polypeptides
KR20200080747A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
AU2020399194A1 (en) 2019-12-10 2022-07-28 Sanofi A method of forming a conjugate of a sulfonamide and a polypeptide
CN113773391B (zh) * 2020-06-09 2023-10-20 宁波鲲鹏生物科技有限公司 一种门冬胰岛素的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886043A (en) * 1972-08-24 1975-05-27 Choay Sa Process for preparing pure porcine beta-trypsin
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4808537A (en) * 1984-10-30 1989-02-28 Phillips Petroleum Company Methanol inducible genes obtained from pichia and methods of use
US4879231A (en) * 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5135868A (en) * 1985-10-25 1992-08-04 Phillips Petroleum Company Cultures of yeast of the genus Pichia altered by site selective genomic modification
US5166329A (en) * 1985-10-25 1992-11-24 Phillips Petroleum Company DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia
US5032516A (en) * 1985-10-25 1991-07-16 Phillips Petroleum Company Pichia pastoris alcohol oxidase II regulatory region
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4857467A (en) * 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5122465A (en) * 1989-06-12 1992-06-16 Phillips Petroleum Company Strains of pichia pastoris created by interlocus recombination
JPH06500470A (ja) * 1990-09-04 1994-01-20 メルク　エンド　カンパニー　インコーポレーテッド メチロトローフ酵母細胞におけるインスリン様成長因子の産生
DE19821866A1 (de) 1998-05-15 1999-11-18 Hoechst Marion Roussel De Gmbh Verfahren zur Katalyse von komplexen Reaktionen großer Moleküle mittels an einem polymeren Träger gebundener Enzyme
AU3910000A (en) 1999-03-22 2000-10-09 Zymogenetics Inc. Improved methods for producing proteins in transformed (pichia)
CZ303658B6 (cs) * 2001-02-01 2013-02-06 F. Hoffmann-La Roche Ag Zpusob rekombinantní produkce trypsinu
US7364892B2 (en) * 2002-09-24 2008-04-29 Novozymes, Inc. Microbial trypsin mutants having chymotrypsin activity and nucleic acids encoding same

Also Published As

Publication number Publication date
ES2370657T3 (es) 2011-12-21
KR20080055843A (ko) 2008-06-19
KR101304958B1 (ko) 2013-09-17
EP1926749A1 (en) 2008-06-04
JP2009507500A (ja) 2009-02-26
AU2006291780A1 (en) 2007-03-22
BRPI0616054B1 (pt) 2019-08-06
CA2621344A1 (en) 2007-03-22
MX2008003362A (es) 2008-03-25
US20100196953A1 (en) 2010-08-05
ATE517919T1 (de) 2011-08-15
WO2007031187A8 (en) 2007-08-16
HK1124341A1 (en) 2009-07-10
CA2621344C (en) 2014-12-16
CN101253196A (zh) 2008-08-27
EP1926749B1 (en) 2011-07-27
PT1926749E (pt) 2011-09-29
US7981635B2 (en) 2011-07-19
AU2006291780B2 (en) 2011-12-08
MY146082A (en) 2012-06-29
IL189887A (en) 2012-02-29
SI1926749T1 (sl) 2011-11-30
JP5027812B2 (ja) 2012-09-19
CN101253196B (zh) 2012-09-05
PL1926749T3 (pl) 2011-12-30
IL189887A0 (en) 2008-11-03
CY1112667T1 (el) 2016-02-10
BRPI0616054A2 (pt) 2011-06-07
BRPI0616054B8 (pt) 2021-05-25
WO2007031187A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AR055428A1 (es) Escision de precursores de insulinas mediante una variante de tripsina
CL2009001214A1 (es) Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
ES2422556T3 (es) Tratamiento de hepatitis vírica
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
BRPI0515470A (pt) processos e intermediários para preparação de inibidores de cisteìna protease
BRPI0510674A (pt) variantes fc otimizadas
GT200500354A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas
AR058753A1 (es) Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
CO6660439A2 (es) Eliminación de serina proteasa por tratamiento con dióxido de silicona finamente dividido
BRPI0615029A2 (pt) processos e intermediários
CR20110453A (es) Combinación de un inhibidor de nucléosido polimerasa con un inhibidor de proteasa macrocíclica y su uso en el tratamiento de hepatitis c, fibrosis hepática y función hepática alterada
GT200600046A (es) Terapia de combinacion
AR070497A1 (es) Composicion detergente que comprende lipasa
AR068556A1 (es) Anticuerpos inmunorreactivos con 5-enolpiruvilshikimato-3-fosfato sintetasa mutante
BRPI0712171A8 (pt) Método para formatar um gráfico e sistema para modificar um gráfico
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
TW200740719A (en) Pyrene organic compound, transistor material and light emitting transistor element
BRPI0618654A8 (pt) variante de zimogênio/protease de fator x/fator xa, ácido nucléico, composição farmacêutica que os contém, vetor, bem como uso dos mesmos
ATE541975T1 (de) Lichtemittierender getufteter teppich
CR10164A (es) Uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de obesidad
AR063570A1 (es) Efectos biologicos mejorados para composiciones que comprenden acido rosmarinico
CR11859A (es) Composición y proceso-356
AR067336A1 (es) Moduladores de calicreina 7
BRPI0913178A2 (pt) Método para produzir um hidrolisado de caseína, hidrolisado de caseína, e, uso de hidrolisado de caseína

Legal Events

Date Code Title Description
FG Grant, registration